Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04412668 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
A Phase 2 study, sponsored by aTyr Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT04412668 is a Phase 2 study that has completed, run by aTyr Pharma. The registered enrollment target is 36 participants.
The verdict
NCT04412668, a Phase 2 study, has completed, sponsored by aTyr Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
Interventions
- DRUG Placebo
- DRUG Efzofitimod 3 mg/kg
- DRUG Efzofitimod 1 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2020-06-04 |
| Est. Completion | 2020-10-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04412668
The ClinicalTrials.gov registry entry for NCT04412668 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is aTyr Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04412668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04412668 about?
NCT04412668 is a clinical study titled "Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19". To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
What is the current status of trial NCT04412668?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2020-06-04. Estimated completion is 2020-10-23.
What interventions are being tested in trial NCT04412668?
The interventions under investigation include: Placebo (DRUG), Efzofitimod 3 mg/kg (DRUG), Efzofitimod 1 mg/kg (DRUG).
Who is sponsoring clinical trial NCT04412668?
This trial is sponsored by aTyr Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.